156 results about "Treponema" patented technology

Disclosed is a vaccine against Lyme Disease or its causative agent Borrelia burgdorferi (sensu stricto or sensu lato) containing a plasmid a DNA encoding a promoter for driving expression in a mammalian cell, DNA encoding a leader peptide for facilitating secretion/release of a prokaryotic protein sequence from a mammalian cell, a DNA encoding Borrelia OspA or OspB, and a DNA encoding a terminator. Disclosed too is an immunogenic composition against Lyme Disease or its causative agent Borrelia burgdorferi (sensu stricto or sensu lato) containing a plasmid comprising a DNA encoding a promoter for driving expression in a mammalian cell, DNA encoding a leader peptide for facilitating secretion/release of a prokaryotic protein sequence from a mammalian cell, a DNA encoding a Borrelia OspC, and a DNA encoding a terminator. And, methods for making and using such vaccines and the immunogenic composition are also disclosed.

The present invention discloses hybridization assay probes, amplification primers, nucleic acid compositions and methods useful for detecting Borrelia nucleic acids. Hybridization assay probes and amplification primers that selectively detect Lyme disease-associated Borrelia and distinguish those Borrelia from Borrelia hermsii are disclosed. Other hybridization probes selectively detect Borrelia hermsii and not Lyme disease-associated Borrelia are also described.

The present invention relates to vaccines for control of Borrelia infections in animal and human populations. In particular, the present invention provides compositions and methods comprising recombinant bacteria engineered to express one or more Borrelia burgdorferi antigens for use as Lyme disease vaccines. In some embodiments, the recombinant bacteria are freeze-dried.

A tablet for insertion into a vagina including 0.01 to 500 mg of a vaginal medication, such as a microbicide, such as cellulose acetate 1,2-benzenedicarboxylate (CAP); 100 to 500 mg of mannitol powder; 50 to 300 mg of inert microcrystalline cellulose; 10 to 80 mg of hydroxypropyl methylcellulose; 50 to 250 mg of glycerol and optionally 2 to 4 mg of at least one preservative which protects against microbicidal contamination and discourages the growth of yeast in the vagina. The tablet which includes CAP as the vaginal medication is vaginally administered before coitus in methods for preventing the sexual transmission of HIV-1, HIV-2, herpesvirus, or an infection caused by Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, Haemophilus ducreyi or Treponema pallidum. The tablet which includes CAP as the vaginal medication is vaginally administered to prevent or treat bacterial vaginosis.

A method and system of reducing the likelihood of an inflammatory disease developing by providing a mucosal adhesive strip to a subject, with the strip provided with at least one of a plurality of agents effective to hinder the growth of spirochetes bacteria in a subject's oral cavity. In certain embodiments, an effective amount of Prevotella intermedia is provided to decrease the incidence of periodontitis and to reduce the progression of Alzheimer's disease. In still other embodiments, the likelihood that a subject will suffer from Alzheimer's disease is reduced by administering via local gingival application to a subject that has been diagnosed with periodontitis an effective amount of an antibiotic effective to kill spirochetes bacteria residing on the subgingival tooth area of the subject.

The invention relates to a trivalent gene recombination vaccine for preventing leptospirosis and a preparation method thereof and aims to effectively prevent infection of leptospira interrogans of different sero-groups with low manufacturing cost. The technical scheme is that: the trivalent gene recombination vaccine for preventing the infection of leptospira interrogans of different sero-groups consists of a lipL32/1 gene, a lipL21 gene and an ompL1/2 gene cloned from a leptospira icterohemorrhagiae genome; a fusion gene lipL32/1-lipL21-ompL1/2 prepared by a technique for gene engineering has a nucleotide sequence and an amino acid sequence shown in a sequence 5; and the lipL32/1 gene is connected with the lipL21 gene, and the lipL21 gene is connected with the ompL1/2 gene through two same flexible peptides shown in a sequence 4.

The invention provides a loop-mediated isothermal amplification method for detecting lyme disease spirochete. DNA (deoxyribonucleic acid) of a sample to be detected is subjected to constant temperature amplification reaction by adopting a FIP (forward inner primer) and a BIP (backward inner primer) and F3 and B3 (shown in Seq ID No.1-4). According to the loop-mediated isothermal amplification method, a LAMP (loop-mediated isothermal amplification) primer constant-temperature amplification technique is used for fast detecting the lyme disease spirochete, and the lyme disease spirochete can be accurately detected from suspected patient serum. The specificity and sensitivity of the method are higher than those of the common PCR (polymerase chain reaction). Different virulence genes of lyme disease spirochetes can be detected, and the method has significance in the aspects of early diagnosis and early treatment of the lyme disease and the like. Investment on an expensive apparatus can be avoided and the method is convenient for grass-root popularization and use.

The invention discloses a detecting method for leptospira, which is based on the quantitative detection technique of nucleic acid isothermal expansion, which is characterized in that a specific primer is used, and the specific area of target gene is expanded utilizing the LAMP technological platform; under the assistance of a series of quality control and internal control detection system, the leptospira is detected in molecule level, which can realize the qualitative and quantitative detection to micro sample. Compared with the prior art, the detecting method for leptospira has the advantages of decreased non-specific expansion because of isothermal expansion, good specificity, fast detection speed, high sensitivity, no need for special equipment, low cost, easy operation, easy popularization and wide application prospect, and is suitable for experimental study, clinical detection and environment detection.

The present invention provides a lyme disease spirochaete detection RPA primer and probe, the RPA primer is designed on the basis of lyme disease spirochaete recA gene, and primer sequences are as shown in Seq ID No: 1 and 2. The probe is designed on the basis of the RPA primer, and has a size of 46-52bp, 5 'end of the probe is marked with FAM, 3' end of the probe is modified by C3Spacer, and dSpacer or THF modification is performed at a position 30bp apart from the 5 'end of the probe. The present invention further provides a kit comprising the RPA primer and the probe. The present invention further provides a lyme disease spirochaete detection RPA method baed on the RPA primer and the probe. By combined use of RPA primer isothermal amplification technology and lateral flow chromatography test paper, lyme disease spirochaetes can be quickly and accurately detected from serum of suspicious patients. The specificity and sensitivity of the method are higher than that of conventional PCR, the method can be used for detecting lyme disease spirochaetes of different pathogenic genotypes, has important significance for lyme disease early diagnosis and treatment and other aspects of the lyme disease, can eliminates excessively high instrument cost, and is easy to promote and use in grassroots.

Mucosal administration of OspA and compositions therefor are disclosed and claimed. More particularly, oral administration of OspA and compositions therefor for eliciting an immunological response against Borrelia burgdorferi, such as a protective response preventive of Lyme disease are disclosed and claimed. Thus, oral Lyme disease vaccines or immunological compositions and methods of use are disclosed and claimed.

The invention discloses a protein chip for detecting pathogen antibodies of blood and cerebrospinal fluid and its preparing method, and the protein chip includes substrate and peculiar-culture or shape protein or polypeptide antigen of array distributed pathogen and contrasted dot coating, where the substrate is a glass substrate; and the antigen and contrasted dot coating refers to 13 antigens with ten indexes including HSV-I, HSV-II, VZV, CMV, EBV, RV, JEV, MV, MT and LP, uniformly distributed on the glass substrate in a dot matrix form, and positive contrast, negative contrast and blank contrast. The protein chip of the invention can obtain multiple-index reacting result only by one reaction, judges infection of different pathogens and has the characters of quickness, high efficiency, accuracy and parallel diagnosis.

The invention discloses a treponema (TP) antibody detection method and a detection kit of the TP antibody detection method. The detection method comprises the following steps of: (a) marking a first TP antigen by a small molecular substance; (b) coating a solid phase material by a second TP antigen; (c) marking an anti-small-molecular substance antibody or other substances capable of being combined with a small molecule by a signal generating substance, and then preparing a signal reporter molecule; (d) carrying out immune reaction between the second TP antigen on the surface of the solid phase material, the first TP antigen marked by the small molecular substance and the TP antibody in a sample, and then carrying out conjugation reaction between the signal reporter molecule and the small molecular substance, thus forming a detachable signal generation substance for detecting the content of the TP antibodies in the sample. The detection kit comprises (a) the first TP antigen marked by the small molecular substance, (b) the solid phase material coated with the second TP antigen, and (c) the signal reporter molecule. By adopting the TP antibody detection method and the detection kit of the TP antibody detection method, the sensitivity and specificity in the detection of the TP antibody can be effectively improved.

The present invention relates, generally, to the production of one or more OspA proteins in plant cells. Heterologous DNA comprising genes encoding one or more desired OspA protein(s) are introduced into plant cells. The one or more OspA protein(s) can be recombinantly-produced in the plant cells, optionally purified from the plant cells, and used as an oral vaccine to prevent the transmission of Lyme disease, particularly by animal vectors. The recombinantly-produced OspA protein(s) can be provided in oral and parenteral formulations. The present invention also relates to oral administration of OspA protein(s) to vaccinate against Lyme disease. The OspA protein(s) may be provided in a dosage form that is suitable for oral administration as a vaccine to prevent an animal from developing Lyme disease after exposure to a source of Borrelia burgdorferi.

The invention relates to a loop-mediated isotheral amplification method (LAMP) for detecting Lyme disease pathogen in tick bodies, which is characterized by taking 16S rRNA gene as the target gene, using special software to design the LAMP for detecting the primers of the Lyme disease pathogen-Borrelia burgdorferi in the tick bodies, then selecting the primer of the specific fragment of the Lyme disease pathogen from the primers, extracting DNA after piercing the ticks to be detected, uniformly mixing the obtained DNA and the reaction buffer, the reaction mixture of the selected primer of the specific fragment and DNA polymerase to carry out amplification, adding loading buffer after activating the amplified product, then placing the mixture into agarose gel containing ethidium bromide to carry out electrophoresis detection and detecting whether the detected ticks carry the Lyme disease pathogen according to whether the specific band occurs after electrophoresis.

The invention discloses a full-automatic ELISA detection device for treponema pallidum on a micro-fluidic chip. The full-automatic ELISA detection device comprises the micro-fluidic chip, a direct-current power source, a fluorescence detection system and a control system. The micro-fluidic chip comprises liquid storage tanks from first to seventh and a main channel, the liquid storage tanks from first to fifth are communicated with an inlet of the main channel through sample inlet channels, an outlet of the main channel is communicated with a sample outlet channel, and the other end of the sample outlet channel is communicated with the seventh liquid storage tank. The invention further discloses a detection method using the full-automatic ELISA detection device for treponema pallidum on the micro-fluidic chip. The full-automatic ELISA detection device has the advantages of being high in mechanization degree, simple in operation procedure, small in size, precise in structure, high in reliability and low in cost, and automatic control is convenient to achieve.

An antigen composition and method for the detection of antibodies to Treponema pallidum and the diagnosis of syphilis are described. The antigen composition contains synthetic cardiolipin and synthetic lecithin. The antigen composition may additionally contain cholesterol and an alcohol. The antigen composition is useful as an immunoreagent in immunoassays for the detection of antibodies associated with T. pallidum infection. The methods are sensitive and specific for T. pallidum infection.

A method for detecting luetin uses TP 0684 and TP 0453 syphilis specific antigens unitedly to make full use of characteristics and advantages of two said antigens for greatly raising sensitivity and specificity of detection. The kit for realizing said method to detect syphilis in early stage is also disclosed.

The present invention describes novel polynucleotides and amino acids of B. hyodysenteriae. These sequences are useful for the diagnosis of B. hyodysenteriae in animals, and for the therapeutic or prophylactic treatment of B. hyodysenteriae in animals. These sequences may also be used in the diagnosis, and therapeutic and/or prophylactic treatment of diseases in animals caused by other Brachyspira species including Treponema, B. alvinipulli, B. alvinipulli, Brachyspira, Harmless Brachyspira, B. murdochii and Brachyspira pilosicoli.

This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.